What "503A compounded" and "research-only" actually mean

Start here: what "FDA-approved" means

FDA approval is not a judgment about a molecule in the abstract. It is a decision about a specific product, made by a specific manufacturer, for a specific indication, backed by a New Drug Application or Biologics License Application that the FDA reviewed. Two practical consequences follow. First, a peptide can be "FDA-approved" for one narrow use and sold under the same popular name for a completely different, unapproved use — elamipretide is approved only for Barth syndrome, but material sold as "SS-31" in wellness contexts is often not the approved product at all. Second, approval says nothing about material sold under the same chemical name by an unrelated seller; the approval belongs to the product, not the molecule.

What 503A means

Section 503A of the Food, Drug & Cosmetic Act creates an exemption from the normal drug-approval process for a licensed pharmacist working in a state-licensed pharmacy (or a licensed physician) who prepares a drug for an individual, identified patient under a valid prescription (FDA). The idea is narrow and old: sometimes a patient needs a formulation that no manufacturer sells — a different strength, an allergen removed, a liquid instead of a pill — and a pharmacist filling that specific need does not need to run a clinical trial first.

A few things follow from that:

• 503A compounding is regulated mainly by state boards of pharmacy, not the FDA directly, and does not require compliance with current Good Manufacturing Practice (cGMP) — the batch-validation standard drug manufacturers must meet.
• The pharmacist can only use bulk substances the FDA has evaluated and placed on its permitted list for 503A use, or substances that are components of an FDA-approved drug (FDA bulk drug substances list).
• It is prescription-specific. A 503A pharmacy generally cannot pre-manufacture stock and sell it without a prescription attached to a named patient.

What 503B means

Section 503B covers outsourcing facilities — larger operations that register with the FDA, follow cGMP, and can compound in batch, without a patient-specific prescription, so that a hospital or clinic can keep product in stock for office use. In exchange for that flexibility, 503B facilities take on real manufacturing obligations: FDA registration, routine inspection, and cGMP validation of every process, closer to what a drug manufacturer does than what a corner pharmacy does.

	503A	503B
Who	Licensed pharmacy or physician	FDA-registered outsourcing facility
Basis	Patient-specific prescription	Can compound without a patient-specific script, for office stock
Batch size	Individual preparations	Can produce in batch
cGMP required	No	Yes
Primary regulator	State board of pharmacy	FDA (plus state)
Bulk substance rule	Must be on the 503A bulks list or a component of an approved drug	Similar substance rules, evaluated separately

A substance being "not compoundable" almost always refers to the 503A bulks list — the one relevant to a retail compounding pharmacy filling an individual prescription, which is the pathway most people interact with.

What "not compoundable" means, and why the FDA puts something there

When the FDA evaluates a substance nominated for the 503A bulks list, it weighs the substance's chemistry, any safety issues raised by its use, the evidence for its effectiveness, and its history of use in compounded products (FDA evaluation criteria). A substance can end up without a compounding pathway for a few different reasons, and they are not interchangeable:

• Insufficient data. The FDA has not seen enough safety evidence to evaluate the substance either way. This is the most common reason, and it is a statement about the evidence available, not a finding of danger.
• An explicit unfavorable vote. Occasionally FDA's Pharmacy Compounding Advisory Committee formally reviews a substance and votes against inclusion — thymosin alpha-1 was voted down 4-17 in December 2024. That is a stronger and more specific signal than simply not yet being reviewed.
• Regulatory status changed. A wave of substances — BPC-157, TB-500, KPV, and others — were removed from FDA's "Category 2" list in April 2026 and moved into a formal Pharmacy Compounding Advisory Committee review scheduled for July 2026. Removal from Category 2 is not the same as approval; it moves a substance out of one review bucket and into another, still without a settled compounding pathway as of this writing.

What "not compoundable" does not mean: it is not a statement that possessing or using the substance is a crime. It is a statement about whether a licensed pharmacist has a lawful path to prepare it for you. Those are different questions — see research peptides and the law for the distinction.

What "research use only" actually means, legally

"Research use only" and "not for human consumption" are labeling claims a seller applies to a product. They are not, by themselves, a legal exemption from drug regulation. The FDA's own framework for this — the "intended use" regulation at 21 CFR 201.128 — looks at the totality of evidence about what a product is intended for: the label, yes, but also advertising, website content, and the circumstances of the sale. A label can be contradicted by everything else about how a product is marketed.

This is not theoretical. In February 2025 the FDA sent a warning letter to a peptide seller stating plainly that despite "research use only" and "not for human consumption" language on the label, evidence from the company's own website established that the products were drugs intended for human use (FDA warning letter, usapeptide.com). More letters followed in 2025 and 2026 to other sellers on the same basis (example). The label alone does not resolve the legal question — it is one input into it.

Practically, research-only material sits outside every FDA-regulated manufacturing, testing, and compounding requirement described above. No agency verifies its purity, its dose accuracy, or its sterility before it reaches a buyer. That is a fact about oversight, independent of the legal question of whether using it constitutes drug use under the law.

What none of these statuses tell you

A status answers a specific, narrow question about regulatory pathway. It does not answer whether a compound works for its marketed purpose, whether a specific seller's material is pure or accurately dosed, or whether it is appropriate for you. Those are separate questions a clinician, not a label, is positioned to help with.

Related reading

• The full FDA-approved peptides list, by status, sourced from Peptra's compound reference.
• Research peptides and the law — the deeper legal framework.
• How to reconstitute a peptide.
• All guides.